Tokyo, Japan

Jun Hirata

USPTO Granted Patents = 1 


 

Average Co-Inventor Count = 28.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jun Hirata – Innovator in Pharmaceutical Compounds

Introduction

Jun Hirata is a notable inventor based in Tokyo, Japan, recognized for his significant contribution to the field of pharmaceutical innovations. He is the author of one patent that centers around a novel compound designed to inhibit RORγ activity, showcasing his expertise in developing therapeutic solutions.

Latest Patents

Jun Hirata's patent is for a Pyrazole amide derivative, which pertains to a compound with the potential to treat and prevent various diseases, including autoimmune, inflammatory, metabolic, and cancers. This invention underscores the ongoing advancements in pharmaceutical compositions aimed at addressing critical health issues.

Career Highlights

Throughout his career, Jun Hirata has collaborated with prominent companies such as Amgen Inc. and Teijin Pharma Limited. His roles in these organizations have contributed significantly to his innovative capabilities, enabling him to develop groundbreaking therapeutic solutions.

Collaborations

In addition to his professional affiliations, Jun Hirata has worked alongside talented professionals, including Hilary Plake Beck and Shon Booker. These collaborations have likely enriched his perspective and approach towards invention and innovation in the pharmaceutical domain.

Conclusion

In conclusion, Jun Hirata exemplifies the role of inventors in the pharmaceutical industry. His patent for a Pyrazole amide derivative not only highlights his ingenuity but also promises potential therapeutic benefits for patients dealing with serious health conditions. His collaborations and work history reflect a commitment to advancing medical science through innovation.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…